We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The location services of the android phones are required in order for the Eversense® app to scan for Bluetooth devices and pair with the Eversense® 365 Smart Transmitter. The Eversense® app does not track your location.
For a list of compatible devices and operating system versions, please go to www.eversensecgm.com/compatibility/
There is no limit to the number of people you can monitor using the Eversense NOW app.
Yes. Go to Main Menu > System Set Up > Help Me Set Up and select the tutorial you would like to review again.
The Eversense® 365 CGM System has not been tested in the following populations: women who are pregnant or nursing, people under the age of 18, critically ill or hospitalized patients, people receiving immunosuppressant therapy, chemotherapy or anti-coagulant therapy, those with another active implantable device, e.g., an implantable defibrillator (passive implants are allowed, e.g., cardiac stents), those with known allergies to or using systemic glucocorticoids (excluding topical, optical or nasal, but including inhaled).
The system’s accuracy hasn’t been tested in these populations, and sensor glucose readings may be inaccurate, resulting in missing a severe low or high glucose event.
The Eversense® Smart Transmitter produces non-ionizing electromagnetic radiation. This means that the transmitter creates a small amount of Electromagnetic Interference (EMI). The amount of EMI that the transmitter produces has been tested and certified as safe for use. If you have any concerns and/or questions about the Eversense® 365 CGM System, we would ask you to contact our Customer Service Team at: eversense.us@ascensia.com or call us at 1-844-736-7348.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1